Immune Monitoring in Cancer Vaccine Clinical Trials: Critical Issues of Functional Flow Cytometry-Based Assays

Table 2

	w/o DNAse	w/o DNAse	w/o DNAse
	NT	SEB	MART-1
% of CD8^+ MART-1+∗	0.0036	0.0039	0.0046
Number of CD8^+ MART-1+¶	34	29	38
	DNAse in culture	DNAse in culture	DNAse in culture
	NT	SEB	MART-1
% of CD8^+ MART-1^+	0.013	0.0081	0.0077
Number of CD8^+ MART-1^+	129	80	75
	DNAse always	DNAse always	DNAse always
	NT	SEB	MART-1
% of CD8^+ MART-1^+	0.015	0.017	0.011
Number of CD8^+ MART-1^+	143	153	103

∗Percentage or ¶number of cells as assessed in an FMT assay, performed on PBMCs from healthy donors, treated and labeled as in Figure 1, with the addition of HLA-A2/peptide tetramer staining at the beginning of culture (HLA-A2*0201 peptide phycoerythrin (PE) tetrameric complexes specific for the Melan-A/MART-1 antigen).